DPP-IV inhibitor therapy increases the levels of endogenous biologically active incretins, which in turn reduce fasting and postprandial glucose levels, reduce HbA1C values, and improve insulin sensitivity and beta-cell function.[3] Thus they hold considerable therapeutic potential for individuals with T2DM. The gene discussed is GCG; the disease is type 2 diabetes mellitus.